New data shows promising advancements in cancer therapeutics by Accent Therapeutics
Accent Therapeutics has revealed promising new preclinical data for its leading clinical programs, ATX-295 and ATX-559, at the prestigious 2025 AACR-NCI-EORTC International Conference on Molecular